Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Clinical trial NCT04876248 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04876248
- Sponsor
- Roswell Park Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-19
- Primary completion
- 2026-12-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.